The oral Janus Kinase (JAK)-1/2 inhibitor baricitinib is being tested in patients with ANA positive, early onset, idiopathic or JIA-associated uveitis in an ongoing international trial (NCT04088409). This evidence concerns the gene BTG3 and juvenile idiopathic arthritis.